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Table 1
Variable n Mean (STD) Median (range)
Age (yr) 42 57.1 (11.5) 59.5 (29, 71)
Early marrow blast % 42 21.4 (27.1) 6 (0, 90)
Factor Frequency Factor Frequency
Secondary AML Cytogenetics
N 33 Favorable/intermediate 1/16
Y 9 Unfavorable/unknown 23/2
FLT3 NPM
Negative 20 Negative 25
Positive 9 Positive 2
# of inductions MRD present
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diedwhile 18 (50%) had relapse-free survival. Median follow-
upwas 17months (range 0.7- 191months) and at last follow-
up, 23 (64%) deaths were documented (8 disease relapse, 13
non-relapse mortality, 2 lost to follow-up). Most common
causes of non-relapse mortality were complications related
to GVHD (31%) and sepsis (31%). In a survival analysis,
engraftment failure and high HCT-comorbidity index had a
trend towards shortened overall survival.
Conclusions: Allogeneic HCT remains a viable treatment
option for patients with CMML, with engraftment failure and
high co-morbidity index being potential poor prognostica-
tors impacting survival. Conventional risk stratifying CMML
models did not predict for HCT outcomes.Figure 1. Survival as a function of early marrow blast percentage
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Introduction: The effect of early response of AML to induc-
tion chemotherapy on transplant outcomes is not well-
characterized. We hypothesize that higher blast count in an
early post-induction bonemarrow biopsy (Day 14marrow) is
associated with inferior outcomes after allogeneic HCT for
AML in ﬁrst remission (CR1).
Methods: We retrospectively reviewed 42 AML patients
(median age 60 years, range 29-71) treated at Seidman
Cancer Center from 2008 to 2014 who had early marrow
evaluation (median 13 days, range 7-14) after induction
chemotherapy and received allogeneic transplant in CR1.
Blast % was calculated from 200 total nucleated cells counted
on marrow aspirate. Variables examined included age, per-
formance status, de novo vs. secondary AML, cytogenetics,
FLT3 / NPM status, incomplete count recovery (CRi), number
of induction cycles, conditioning regimen, graft source,
minimal residual disease (MRD) and presence of acute and
chronic graft-versus-host disease (GVHD). Relapse-free sur-
vival (RFS) was deﬁned as time from transplant to relapse or
death in remission. Survival distribution from time of
transplant was estimated using Kaplan-Meier methods and
difference of survival and RFS between groups was examined
by log-rank. Effect of continuous variables on survival was
estimated using Cox model.
Results: Patient characteristics are summarized in Table 1.
RFS at 2 years did not differ between those with <6% or
>5% marrow blasts at Day 14 (58 vs. 58%, p¼.7). Survival at
2 years also did not differ between the 2 groups (43 vs.
49%, p¼1; Figure 1). Use of different blast cutoff values did
not elicit a difference in 2-year RFS or survival. A higher
blast percentage did not result in increased hazard of death
(HR 1, p¼.72). Having 2 induction cycles (32 vs. 53%,
p¼.18), graft source of cord blood vs. other (28 vs. 58%;
p¼.16), and ECOG performance status 1 vs. 0 (27 vs. 42%;
p¼.32) may be associated with inferior survival at 2 years,
although this did not reach statistical signiﬁcance likely
due to limited sample size.
Conclusion: Apparent chemotherapy resistance based
on higher residual blast percent early after induction
chemotherapy likely carries no signiﬁcant risk of adverse
outcome after AML transplant in ﬁrst remission. Utility of theDay 14 marrow evaluation in predicting outcomes after
allogeneic transplant in CR1 remains unclear.253
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Clinical trials have shown the efﬁcacy of clofarabine (Clo),
ﬂudarabine (Flu) and busulfan (Bu) combinations in he-
matopoietic stem cell transplantation (HSCT) for myeloid
Characteristic N (%)
Sex
Male 13 (32)
Female 6 (68)
Lymphoma Type
Hodgkin’s 7 (37)
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more affordable cladribine (Clad) can supplant Clo with or
without epigenetic modulators, using panobinostat (Pano)
and 5-aza-20-deoxycytidine (DAC) as prototype represen-
tatives of such agents. Both [Clad+Flu+Bu] and [Clo+-
Flu+Bu] combinations showed synergistic cytotoxicity in
KBM3/Bu2506, HL60 and OCI-AML3 cell lines with 60%-80%
inhibition of proliferation. Drug exposure resulted in acti-
vation of the ATM pathway, increase in histone modi-
ﬁcations with corresponding decreased levels of HDAC3,
HDAC4, HDAC5 and SirT7, decrease in mitochondrial
membrane potential, activation of apoptosis and stress
signaling pathways, and down-regulation of the pro-sur-
vival AKT pathway. Similarly, these drug combinations
activated DNA-damage response and apoptosis in primary
cell samples from AML patients. At lower concentrations of
Clad/Clo, Flu and Bu, inclusion of Pano and DAC yielded a
signiﬁcant increase in histone modiﬁcations and DNA
demethylations, resulting in further enhanced cell killing.
Inclusion of Pano decreased histone deacetylases and
demethylases. The presence of DAC decreased the level of
DNA methyl transferase 1 (DNMT1), which consequently
increased the levels of cell-cycle checkpoint proteins
such as P16/INK4a, P15/INK4b and P21/Waf1/Cip1. We
also demonstrated the DNA demethylating activity of
Clad and Clo, which may be augmented by DAC activity
and caused degradation of b-catenin in cells exposed to
[Clad/Clo+Flu+Bu+DAC+Pano]. Increased demethylations of
the gene promoters for SFRP1, DKK3 and WIF1 were
observed with concomitant up-regulation of their expres-
sions; the encoded proteins are known to antagonize
the pro-survival Wnt/b-catenin pathway. The overlapping
activities of [Clad/Clo+Flu+Bu], Pano and DAC in DNA-
damage formation, histone modiﬁcations, DNA deme-
thylation and apoptosis may explain their synergism. A
proposed model for the observed drug synergism in AML
cells is shown below. Our results provide a basis for sup-
planting Clo with Clad and for including epigenetic modi-
ﬁers in the pre-HSCT conditioning regimen for myeloid
leukemia patients.NHL 7 (37)
CLL/PLL 5 (26)
Disease Status at Transplant
CR/CRU 5 (26)LYMPHOMA/MULTIPLE MYELOMA
PR 10 (53)
SD 3 (16)
PD 1 (5)
Conditioning Intensity
MA 11 (58)
NMA 8 (42)
Donor Relation
Parent 4 (21)
Child 4 (21)
Sibling 11 (58)254
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Introduction: Haploidentical transplantation with post-
transplant cyclophosphamide (PTCy) using the non-mye-
loablative (NMA) conditioning regimen with Flu/Cy/TBI
has been associated with low treatment-related mortality
(TRM) for lymphoma patients. We investigated a more
intense, melphalan-based regimen in an attempt to improve
disease control post-transplant for advanced lymphoma
patients.
Methods: All patients who received a bone marrow Hap-
loSCT at MD Anderson for high-risk lymphoma/CLL after
2009 were reviewed. Initially, patients received myeloa-
blative (MA) conditioning with ﬂudarabine and melphalan
140 mg/m2(FM140) +/- thiotepa 5-10 mg/kg. Due to con-
cerns of increased TRM, a lower intensity conditioning
regimen with melphalan 100 mg/m2 (FM100) +/- thiotepa
5 mg/kg or 2Gy TBI was adopted. Rituximabwas included for
CD20+ disease. GVHD prophylaxis consisted of tacrolimus/
MMF/PTCy, as previously described. One patient was treated
with the Flu/Cy/TBI regimen. Univariate comparisons were
done utilizing the log-rank test.
Results: Nineteen patients, with a median age of 45 years
(range 20-62) underwent HaploSCT for advanced lymphoma.
Characteristics of these patients are described in the Table.
Seventy-four percent of patients were not in remission at
transplant. Of the patients not in CR/CRU at transplant, 9/14
(64%) remain alive. Engraftment occurred in 18 patients
(95%), with one incident of primary graft failure. Best
chimerism was full donor in 16/19 (84%) of patients. Cumu-
lative incidence (CI) of grade II-IV acute GVHDwas 44% at day
100. Only 2 patients developed chronic GVHD, 1 limited, 1
extensive. After a median follow-up time of 22 months,
median OS and PFS for this group was 63% and 52%,
respectively. The 2-year CI of TRM and disease relapse were
11% and 26%. PFS at 2 years for patients receiving NMA
conditioning was 70% compared to 31% in patients receiving
MA conditioning (p¼0.29).
Conclusions: FM100 regimen appears at least as effective as
FM140 as conditioning for patients with advanced lym-
phoma receiving HaploSCT, with excellent disease control
